Nov. 18, 2013: Bayer HealthCare, Inception Sciences and Versant Ventures Join Forces to Develop Innovative Therapeutics for Retinal Eye Diseases.
Bayer HealthCare has entered into an exclusive collaboration with Inception Sciences, Inc. and Versant Ventures. Inception Sciences and Bayer will jointly conduct early research in the area of ophthalmology, in a newly created company called “Inception 4”. The goal of this new alliance is to develop treatment options, focused on a novel target and pathway, for patients with eye diseases, such as wet age-related macular degeneration and geographic atrophy.
Dec. 12, 2012: The In Vivo Blog 2012 Nominee: Alliance Deal of the Year: Versant/Roche/Inception 3
Oct. 10, 2012: Press Release
Roche Announces Alliance to Discover Novel Treatments for Sensorineural Hearing Loss
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an exclusive partnership with Versant Ventures and Inception Sciences to create a drug discovery incubator, Inception 3, for the treatment of sensorineural hearing loss.
Nov. 29, 2011: Fresh Off Amira Success, Versant’s Bolzon and San Diego’s Prasit Begin Anew with Inception. See Xconomy.com.
July 27, 2011: Versant Supports Biotech Incubator From Amira Co-Founder. See Venture Capital Dispatch for full article